Experienced in Acquired Amegakaryocytic Thrombocytopenia

Gerlinde Egerer

Heidelberg, BW, DE 
Experienced in Acquired Amegakaryocytic Thrombocytopenia
Heidelberg, BW, DE 
OverviewLocationsClinical Research

Overview

Gerlinde Egerer practices in Heidelberg, Germany. Egerer is rated as an Experienced expert by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. Their top areas of expertise are Adult Soft Tissue Sarcoma, Febrile Neutropenia, Endometrial Stromal Sarcoma, Parainfluenza, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 91 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Acquired Amegakaryocytic Thrombocytopenia.

Locations

Heidelberg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib - a Randomized, Controlled Trial
Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib - a Randomized, Controlled Trial
Enrollment Status: Terminated
Publish Date: September 22, 2021
Intervention Type: Drug
Study Drug: Pazopanib
Study Phase: Phase 4
A Phase II Window-of-opportunity Study of Preoperative Therapy With Pazopanib (Votrient®) in High-risk Soft Tissue Sarcoma
A Phase II Window-of-opportunity Study of Preoperative Therapy With Pazopanib (Votrient®) in High-risk Soft Tissue Sarcoma
Enrollment Status: Terminated
Publish Date: January 26, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

91 Total Publications

CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial.
CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial.
Journal: ESMO open
Published: April 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Egerer's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile